Gentian Diagnostics (Norway) Performance
| GENT Stock | NOK 58.00 0.40 0.68% |
Gentian Diagnostics has a performance score of 3 on a scale of 0 to 100. The company retains a Market Volatility (i.e., Beta) of -0.0527, which attests to not very significant fluctuations relative to the market. As returns on the market increase, returns on owning Gentian Diagnostics are expected to decrease at a much lower rate. During the bear market, Gentian Diagnostics is likely to outperform the market. Gentian Diagnostics right now retains a risk of 2.13%. Please check out Gentian Diagnostics standard deviation, total risk alpha, treynor ratio, as well as the relationship between the jensen alpha and sortino ratio , to decide if Gentian Diagnostics will be following its current trending patterns.
Risk-Adjusted Performance
Weak
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Gentian Diagnostics AS are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. Despite quite persistent essential indicators, Gentian Diagnostics is not utilizing all of its potentials. The current stock price mess, may contribute to short-term losses for the institutional investors. ...more
| Begin Period Cash Flow | 158 M | |
| Total Cashflows From Investing Activities | -12.8 M |
Gentian |
Gentian Diagnostics Relative Risk vs. Return Landscape
If you would invest 5,600 in Gentian Diagnostics AS on October 29, 2025 and sell it today you would earn a total of 200.00 from holding Gentian Diagnostics AS or generate 3.57% return on investment over 90 days. Gentian Diagnostics AS is generating 0.0815% of daily returns and assumes 2.1284% volatility on return distribution over the 90 days horizon. Simply put, 19% of stocks are less volatile than Gentian, and 99% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Gentian Diagnostics Target Price Odds to finish over Current Price
The tendency of Gentian Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 58.00 | 90 days | 58.00 | about 12.64 |
Based on a normal probability distribution, the odds of Gentian Diagnostics to move above the current price in 90 days from now is about 12.64 (This Gentian Diagnostics AS probability density function shows the probability of Gentian Stock to fall within a particular range of prices over 90 days) .
Assuming the 90 days trading horizon Gentian Diagnostics AS has a beta of -0.0527. This usually indicates as returns on the benchmark increase, returns on holding Gentian Diagnostics are expected to decrease at a much lower rate. During a bear market, however, Gentian Diagnostics AS is likely to outperform the market. Additionally Gentian Diagnostics AS has an alpha of 0.075, implying that it can generate a 0.075 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Gentian Diagnostics Price Density |
| Price |
Predictive Modules for Gentian Diagnostics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Gentian Diagnostics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Gentian Diagnostics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Gentian Diagnostics is not an exception. The market had few large corrections towards the Gentian Diagnostics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Gentian Diagnostics AS, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Gentian Diagnostics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.07 | |
β | Beta against Dow Jones | -0.05 | |
σ | Overall volatility | 1.67 | |
Ir | Information ratio | 0.0001 |
Gentian Diagnostics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Gentian Diagnostics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Gentian Diagnostics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| The company reported the revenue of 83.11 M. Net Loss for the year was (24.79 M) with profit before overhead, payroll, taxes, and interest of 56.83 M. | |
| Gentian Diagnostics AS has accumulated about 114.94 M in cash with (27.05 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.5. | |
| Roughly 55.0% of the company shares are held by company insiders |
Gentian Diagnostics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Gentian Stock often depends not only on the future outlook of the current and potential Gentian Diagnostics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Gentian Diagnostics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 15.4 M | |
| Cash And Short Term Investments | 114.9 M |
Gentian Diagnostics Fundamentals Growth
Gentian Stock prices reflect investors' perceptions of the future prospects and financial health of Gentian Diagnostics, and Gentian Diagnostics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Gentian Stock performance.
| Return On Equity | -0.17 | |||
| Return On Asset | -0.0871 | |||
| Profit Margin | (0.27) % | |||
| Operating Margin | (0.27) % | |||
| Current Valuation | 541.55 M | |||
| Shares Outstanding | 15.42 M | |||
| Price To Book | 4.05 X | |||
| Price To Sales | 6.01 X | |||
| Revenue | 83.11 M | |||
| EBITDA | (17.44 M) | |||
| Cash And Equivalents | 114.94 M | |||
| Cash Per Share | 8.50 X | |||
| Total Debt | 18.58 M | |||
| Debt To Equity | 0.11 % | |||
| Book Value Per Share | 10.23 X | |||
| Cash Flow From Operations | (27.05 M) | |||
| Earnings Per Share | (1.72) X | |||
| Total Asset | 212.77 M | |||
About Gentian Diagnostics Performance
By examining Gentian Diagnostics' fundamental ratios, stakeholders can obtain critical insights into Gentian Diagnostics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Gentian Diagnostics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Gentian Diagnostics AS researches, develops, and produces biochemical reagents for use in medical diagnostics and research in Europe, Asia, the United States. The company was founded in 2001 and is headquartered in Moss, Norway. GENTIAN DIAGNOSTIC is traded on Oslo Stock Exchange in Norway.Things to note about Gentian Diagnostics performance evaluation
Checking the ongoing alerts about Gentian Diagnostics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Gentian Diagnostics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| The company reported the revenue of 83.11 M. Net Loss for the year was (24.79 M) with profit before overhead, payroll, taxes, and interest of 56.83 M. | |
| Gentian Diagnostics AS has accumulated about 114.94 M in cash with (27.05 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.5. | |
| Roughly 55.0% of the company shares are held by company insiders |
- Analyzing Gentian Diagnostics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Gentian Diagnostics' stock is overvalued or undervalued compared to its peers.
- Examining Gentian Diagnostics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Gentian Diagnostics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Gentian Diagnostics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Gentian Diagnostics' stock. These opinions can provide insight into Gentian Diagnostics' potential for growth and whether the stock is currently undervalued or overvalued.
Other Information on Investing in Gentian Stock
Gentian Diagnostics financial ratios help investors to determine whether Gentian Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Gentian with respect to the benefits of owning Gentian Diagnostics security.